 |
PDBsum entry 4jz1
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
4jz1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
Crystal structure of matriptase in complex with inhibitor
|
|
Structure:
|
 |
Suppressor of tumorigenicity 14 protein. Chain: a. Fragment: unp residues 615-855. Synonym: matriptase, membrane-type serine protease 1, mt-sp1, prostamin, serine protease 14, serine protease tadg-15, tumor- associated differentially-expressed gene 15 protein. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: st14, prss14, snc19, tadg15. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.216
|
R-free:
|
0.241
|
|
|
Authors:
|
 |
H.S.Subramanya,B.C.Ravi,K.N.Ashok,G.Chakshusmathi,K.S.Ramesh
|
|
Key ref:
|
 |
R.Goswami
et al.
(2013).
Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.
Acs Med Chem Lett,
4,
1152-1157.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
02-Apr-13
|
Release date:
|
26-Feb-14
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q9Y5Y6
(ST14_HUMAN) -
Suppressor of tumorigenicity 14 protein from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
855 a.a.
241 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Acs Med Chem Lett
4:1152-1157
(2013)
|
|
PubMed id:
|
|
|
|
|
| |
|
Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.
|
|
R.Goswami,
S.Mukherjee,
G.Wohlfahrt,
C.Ghadiyaram,
J.Nagaraj,
B.R.Chandra,
R.K.Sistla,
L.K.Satyam,
D.S.Samiulla,
A.Moilanen,
H.S.Subramanya,
M.Ramachandra.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Matriptase belongs to trypsin-like serine proteases involved in matrix
remodeling/degradation, growth regulation, survival, motility, and cell
morphogenesis. Herein, we report a structure-based approach, which led to the
discovery of sulfonamide and amide derivatives of pyridyl bis(oxy)benzamidine as
potent and selective matriptase inhibitors. Co-crystal structures of selected
compounds in complex with matriptase supported compound designing. Additionally,
WaterMap analyses indicated the possibility of occupying a distinct pocket
within the catalytic domain, exploration of which resulted in >100-fold
improvement in potency. Co-crystal structure of 10 with matriptase revealed
critical interactions leading to potent target inhibition and selectivity
against other serine proteases.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |